59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D)
T1D management in children < age 6 yrs is challenging due to unpredictable food intake and activity. Efficacy of AID with the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ) in this age group has not been well studied. Data included 95 children with T1D age 2 to < 6 yrs (age 3.9...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 72 |
| creator | PAUL WADWA, R. REED, ZACHARIAH BUCKINGHAM, BRUCE A. DEBOER, MARK D. EKHLASPOUR, LAYA COBRY, ERIN C. SCHOELWER, MELISSA BERGET, CARI LUM, JOHN W. KOLLMAN, CRAIG BECK, ROY BRETON, MARC D. TRIAL STUDY GROUP, PEDAP |
| description | T1D management in children < age 6 yrs is challenging due to unpredictable food intake and activity. Efficacy of AID with the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ) in this age group has not been well studied. Data included 95 children with T1D age 2 to < 6 yrs (age 3.9±1.2 yrs, 46% male, 75 % non-Hispanic white, 34% on multiple daily injections) enrolled in a 13-week extended use phase of a randomized trial of closed loop control (CLC) with CIQ. In this phase, the group assigned to CLC for the initial 13 weeks continued on CLC (CLC-CLC) and those initially using standard care (SC) were placed on CLC (SC-CLC). CGM time in range 70-180 mg/dL (TIR) was the primary outcome. The SC-CLC group (n=33) increased TIR using CLC in the extension compared to the SC period (68±9% vs. 56±13%, p |
| doi_str_mv | 10.2337/db23-59-OR |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2849360678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2849360678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1048-689835cb8a814a39a684934de91d83348020295bc5a5ca90f7116163241f70ac3</originalsourceid><addsrcrecordid>eNotkM1Kw0AUhQdRsFY3PsGAm1aIzk9-ZtyFpNaCUCgt6GqYJDc2JU3qTKJm58I38A19ElMrd3Hg8PFdOAhdUnLDOA9us4Rxx5POfHGEBlRy6XAWPB2jASGUOTSQwSk6s3ZDCPH7G6CvP_gOT8suhW2R4qiuGlOX-L1o1njy0UCVQYZXFnCd47Bt6q1u-mJW2bYsKhxDWbyB6fAonMVj3DfRuigzAxUOXwCzn89vHz-DNvZgXHY7wBTHhU6gAYtHSxqPz9FJrksLF_85RKv7yTJ6cB7n01kUPjopJa5wfCEF99JEaEFdzaX2hSu5m4GkmeDcFYQRJr0k9bSXaknygFKf-py5NA-ITvkQXR28O1O_tmAbtalbU_UvFdur-kkC0VPXByo1tbUGcrUzxVabTlGi9iur_crKk2q-4L8_XGxV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849360678</pqid></control><display><type>article</type><title>59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>PAUL WADWA, R. ; REED, ZACHARIAH ; BUCKINGHAM, BRUCE A. ; DEBOER, MARK D. ; EKHLASPOUR, LAYA ; COBRY, ERIN C. ; SCHOELWER, MELISSA ; BERGET, CARI ; LUM, JOHN W. ; KOLLMAN, CRAIG ; BECK, ROY ; BRETON, MARC D. ; TRIAL STUDY GROUP, PEDAP</creator><creatorcontrib>PAUL WADWA, R. ; REED, ZACHARIAH ; BUCKINGHAM, BRUCE A. ; DEBOER, MARK D. ; EKHLASPOUR, LAYA ; COBRY, ERIN C. ; SCHOELWER, MELISSA ; BERGET, CARI ; LUM, JOHN W. ; KOLLMAN, CRAIG ; BECK, ROY ; BRETON, MARC D. ; TRIAL STUDY GROUP, PEDAP</creatorcontrib><description><![CDATA[T1D management in children < age 6 yrs is challenging due to unpredictable food intake and activity. Efficacy of AID with the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ) in this age group has not been well studied. Data included 95 children with T1D age 2 to < 6 yrs (age 3.9±1.2 yrs, 46% male, 75 % non-Hispanic white, 34% on multiple daily injections) enrolled in a 13-week extended use phase of a randomized trial of closed loop control (CLC) with CIQ. In this phase, the group assigned to CLC for the initial 13 weeks continued on CLC (CLC-CLC) and those initially using standard care (SC) were placed on CLC (SC-CLC). CGM time in range 70-180 mg/dL (TIR) was the primary outcome. The SC-CLC group (n=33) increased TIR using CLC in the extension compared to the SC period (68±9% vs. 56±13%, p<0.001) with no significant change in hypoglycemia (%CGM < 54 mg/dL 0.4±0.3% vs. 0.5±0.6%, p=0.03). TIR increased within the first week of CLC use similar to the first 13 weeks of AID use for the CLC-CLC group (Figure). CLC training was completed virtually for 82% of the SC-CLC group. The CLC-CLC group (n=62) maintained TIR (71±11% vs. 70±10%, p=0.80) with slightly lower rates of hypoglycemia (%CGM < 54 mg/dL 0.5±0.4% vs. 0.6±0.5%, p=0.08). In conclusion, these data show that in young children age 2 to < 6, CLC with Control-IQ technology leads to increased TIR without an increase in time in hypoglycemia.]]></description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db23-59-OR</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Age ; Children ; Diabetes ; Diabetes mellitus (insulin dependent) ; Food intake ; Hypoglycemia ; Insulin ; Intelligence</subject><ispartof>Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1048-689835cb8a814a39a684934de91d83348020295bc5a5ca90f7116163241f70ac3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>PAUL WADWA, R.</creatorcontrib><creatorcontrib>REED, ZACHARIAH</creatorcontrib><creatorcontrib>BUCKINGHAM, BRUCE A.</creatorcontrib><creatorcontrib>DEBOER, MARK D.</creatorcontrib><creatorcontrib>EKHLASPOUR, LAYA</creatorcontrib><creatorcontrib>COBRY, ERIN C.</creatorcontrib><creatorcontrib>SCHOELWER, MELISSA</creatorcontrib><creatorcontrib>BERGET, CARI</creatorcontrib><creatorcontrib>LUM, JOHN W.</creatorcontrib><creatorcontrib>KOLLMAN, CRAIG</creatorcontrib><creatorcontrib>BECK, ROY</creatorcontrib><creatorcontrib>BRETON, MARC D.</creatorcontrib><creatorcontrib>TRIAL STUDY GROUP, PEDAP</creatorcontrib><title>59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D)</title><title>Diabetes (New York, N.Y.)</title><description><![CDATA[T1D management in children < age 6 yrs is challenging due to unpredictable food intake and activity. Efficacy of AID with the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ) in this age group has not been well studied. Data included 95 children with T1D age 2 to < 6 yrs (age 3.9±1.2 yrs, 46% male, 75 % non-Hispanic white, 34% on multiple daily injections) enrolled in a 13-week extended use phase of a randomized trial of closed loop control (CLC) with CIQ. In this phase, the group assigned to CLC for the initial 13 weeks continued on CLC (CLC-CLC) and those initially using standard care (SC) were placed on CLC (SC-CLC). CGM time in range 70-180 mg/dL (TIR) was the primary outcome. The SC-CLC group (n=33) increased TIR using CLC in the extension compared to the SC period (68±9% vs. 56±13%, p<0.001) with no significant change in hypoglycemia (%CGM < 54 mg/dL 0.4±0.3% vs. 0.5±0.6%, p=0.03). TIR increased within the first week of CLC use similar to the first 13 weeks of AID use for the CLC-CLC group (Figure). CLC training was completed virtually for 82% of the SC-CLC group. The CLC-CLC group (n=62) maintained TIR (71±11% vs. 70±10%, p=0.80) with slightly lower rates of hypoglycemia (%CGM < 54 mg/dL 0.5±0.4% vs. 0.6±0.5%, p=0.08). In conclusion, these data show that in young children age 2 to < 6, CLC with Control-IQ technology leads to increased TIR without an increase in time in hypoglycemia.]]></description><subject>Age</subject><subject>Children</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Food intake</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Intelligence</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkM1Kw0AUhQdRsFY3PsGAm1aIzk9-ZtyFpNaCUCgt6GqYJDc2JU3qTKJm58I38A19ElMrd3Hg8PFdOAhdUnLDOA9us4Rxx5POfHGEBlRy6XAWPB2jASGUOTSQwSk6s3ZDCPH7G6CvP_gOT8suhW2R4qiuGlOX-L1o1njy0UCVQYZXFnCd47Bt6q1u-mJW2bYsKhxDWbyB6fAonMVj3DfRuigzAxUOXwCzn89vHz-DNvZgXHY7wBTHhU6gAYtHSxqPz9FJrksLF_85RKv7yTJ6cB7n01kUPjopJa5wfCEF99JEaEFdzaX2hSu5m4GkmeDcFYQRJr0k9bSXaknygFKf-py5NA-ITvkQXR28O1O_tmAbtalbU_UvFdur-kkC0VPXByo1tbUGcrUzxVabTlGi9iur_crKk2q-4L8_XGxV</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>PAUL WADWA, R.</creator><creator>REED, ZACHARIAH</creator><creator>BUCKINGHAM, BRUCE A.</creator><creator>DEBOER, MARK D.</creator><creator>EKHLASPOUR, LAYA</creator><creator>COBRY, ERIN C.</creator><creator>SCHOELWER, MELISSA</creator><creator>BERGET, CARI</creator><creator>LUM, JOHN W.</creator><creator>KOLLMAN, CRAIG</creator><creator>BECK, ROY</creator><creator>BRETON, MARC D.</creator><creator>TRIAL STUDY GROUP, PEDAP</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20230620</creationdate><title>59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D)</title><author>PAUL WADWA, R. ; REED, ZACHARIAH ; BUCKINGHAM, BRUCE A. ; DEBOER, MARK D. ; EKHLASPOUR, LAYA ; COBRY, ERIN C. ; SCHOELWER, MELISSA ; BERGET, CARI ; LUM, JOHN W. ; KOLLMAN, CRAIG ; BECK, ROY ; BRETON, MARC D. ; TRIAL STUDY GROUP, PEDAP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1048-689835cb8a814a39a684934de91d83348020295bc5a5ca90f7116163241f70ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Children</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Food intake</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Intelligence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PAUL WADWA, R.</creatorcontrib><creatorcontrib>REED, ZACHARIAH</creatorcontrib><creatorcontrib>BUCKINGHAM, BRUCE A.</creatorcontrib><creatorcontrib>DEBOER, MARK D.</creatorcontrib><creatorcontrib>EKHLASPOUR, LAYA</creatorcontrib><creatorcontrib>COBRY, ERIN C.</creatorcontrib><creatorcontrib>SCHOELWER, MELISSA</creatorcontrib><creatorcontrib>BERGET, CARI</creatorcontrib><creatorcontrib>LUM, JOHN W.</creatorcontrib><creatorcontrib>KOLLMAN, CRAIG</creatorcontrib><creatorcontrib>BECK, ROY</creatorcontrib><creatorcontrib>BRETON, MARC D.</creatorcontrib><creatorcontrib>TRIAL STUDY GROUP, PEDAP</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PAUL WADWA, R.</au><au>REED, ZACHARIAH</au><au>BUCKINGHAM, BRUCE A.</au><au>DEBOER, MARK D.</au><au>EKHLASPOUR, LAYA</au><au>COBRY, ERIN C.</au><au>SCHOELWER, MELISSA</au><au>BERGET, CARI</au><au>LUM, JOHN W.</au><au>KOLLMAN, CRAIG</au><au>BECK, ROY</au><au>BRETON, MARC D.</au><au>TRIAL STUDY GROUP, PEDAP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D)</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2023-06-20</date><risdate>2023</risdate><volume>72</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract><![CDATA[T1D management in children < age 6 yrs is challenging due to unpredictable food intake and activity. Efficacy of AID with the Tandem t:slim X2 insulin pump with Control-IQ technology (CIQ) in this age group has not been well studied. Data included 95 children with T1D age 2 to < 6 yrs (age 3.9±1.2 yrs, 46% male, 75 % non-Hispanic white, 34% on multiple daily injections) enrolled in a 13-week extended use phase of a randomized trial of closed loop control (CLC) with CIQ. In this phase, the group assigned to CLC for the initial 13 weeks continued on CLC (CLC-CLC) and those initially using standard care (SC) were placed on CLC (SC-CLC). CGM time in range 70-180 mg/dL (TIR) was the primary outcome. The SC-CLC group (n=33) increased TIR using CLC in the extension compared to the SC period (68±9% vs. 56±13%, p<0.001) with no significant change in hypoglycemia (%CGM < 54 mg/dL 0.4±0.3% vs. 0.5±0.6%, p=0.03). TIR increased within the first week of CLC use similar to the first 13 weeks of AID use for the CLC-CLC group (Figure). CLC training was completed virtually for 82% of the SC-CLC group. The CLC-CLC group (n=62) maintained TIR (71±11% vs. 70±10%, p=0.80) with slightly lower rates of hypoglycemia (%CGM < 54 mg/dL 0.5±0.4% vs. 0.6±0.5%, p=0.08). In conclusion, these data show that in young children age 2 to < 6, CLC with Control-IQ technology leads to increased TIR without an increase in time in hypoglycemia.]]></abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db23-59-OR</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2849360678 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Age Children Diabetes Diabetes mellitus (insulin dependent) Food intake Hypoglycemia Insulin Intelligence |
| title | 59-OR: Glycemic Control with Extended Use of Automated Insulin Delivery (AID) in Children Age 2–6 Years with Type 1 Diabetes (T1D) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=59-OR:%20Glycemic%20Control%20with%20Extended%20Use%20of%20Automated%20Insulin%20Delivery%20(AID)%20in%20Children%20Age%202%E2%80%936%20Years%20with%20Type%201%20Diabetes%20(T1D)&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=PAUL%20WADWA,%20R.&rft.date=2023-06-20&rft.volume=72&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db23-59-OR&rft_dat=%3Cproquest_cross%3E2849360678%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2849360678&rft_id=info:pmid/&rfr_iscdi=true |